Andrew J. Murphy, Ph.D.

Andrew J. Murphy, Ph.D.

Executive Vice President, Co-Chief Scientific OfficeratRegeneron Pharmaceuticals· In proxies 2021–2025

Pay in FY2024-1% from the year before · Regeneron Pharmaceuticals stock -18.9% the same year

Andrew J. Murphy, Ph.D. was paid $8.4M in FY2024 (Dec), down 1%. Regeneron Pharmaceuticals stock fell 18.9% that year.

Pay$100 in the stock at the end of FY20 → $147
Pay is from the Summary Compensation Table of each Regeneron Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Regeneron PharmaceuticalsPublic company · 5 yr
    • Executive Vice President, Co-Chief Scientific Officer2021 – Present · 5 yrStock in role +66%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?